Table 2.
Syndrome nodules | Genes and germline mutations @ | Mutated sensor moleule | Tissue over-functioning | Predominat hyperplasia | Progress to or adenomas – – – – – – – – – |
|
---|---|---|---|---|---|---|
Sporadic | Germline | |||||
origin | origin | |||||
NSHPT# | CASR= | CaS-R | Parathyroid | Yes | Rare | No |
CNT | TSHR+ | TSH-R | Thyroid follicle | Yes | Yes | Yes |
FMPP | LHR+ | LH-R | Leydig cell of testis | Yes | Rare | Yes |
OHSS | FSHR+ | FSH-R | Corpus luteum of pregnancy | Yes | Yes | No |
HAIIIA | KCNJ5− | Kir3.4 | Adrenal cortex | Yes | Yes | Yes |
Abbreviations: Congenital neonatal thyrotoxicosis CNT; Neonatal severe primary hyperparathyroidism NSHPT; hyperaldosteronism type III HAIII; Familial male-limited precocious puberty FMPP; Ovarian hyperstimulation syndrome OHSS. CaS-R extracellular calcium sensing receptor; TSH-R TSH receptor; LH-R LH receptor; FSH-R FSH receptor; Kir3.4 inward rectifying potassium channel subunit 3.4;.
Mutation types are: − heterozygous loss of function (inactivation); = homozygous loss of function (inactivation); + heterozygous gain of function (activation).